Intratumoral and Peritumoral Habitat Radiomics of MRI Predict Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy in Oral Squamous Cell Carcinoma
CompletedOBSERVATIONAL
Enrollment
225
Participants
Timeline
Start Date
December 1, 2023
Primary Completion Date
December 1, 2023
Study Completion Date
December 1, 2023
Conditions
Pathologic Complete Response
Trial Locations (1)
430000
Hubei Cancer Hospitla, Wuhan
All Listed Sponsors
collaborator
Hubei Cancer Hospital
OTHER
lead
Zilong Yuan
OTHER
NCT06854107 - Intratumoral and Peritumoral Habitat Radiomics of MRI Predict Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy in Oral Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter